TSO3 Inc, a sterilization technology manufacturer, has announced that it has received the first purchase orders from the United States for its Sterizone sterilization system. The Sterizone VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
With a 75-pound load capacity and a short cycle time, the Sterizone VP4 Sterilizer is designed to increase throughput and lower sterilization cost. The unit is a dual sterilant, low-temperature sterilization system that uses vaporized hydrogen peroxide (H2O2) and ozone. A single cycle can sterilize a large number and wide range of compatible devices, reducing costs and the potential for errors. The Sterizone automatically adjusts the quantity of injected sterilant based on the load composition, weight, and temperature, according to the company.
“Our vision is to create the improved standard in healthcare sterile reprocessing. After spending years in development and working our way through the regulatory demands outlined when launching a new and novel technology, we have now received the first orders,” said R.M. (Ric) Rumble, president and CEO of TSO3. “Every week the list of identified customer targets grows and our pipeline of quotations increases. We feel very good about the product’s initial launch and are working to implement even more ways to increase market awareness for our superior sterilizer.”
For more information, visit the TSO3 website.